Swiss Dental Solutions AG partners with Gilde Healthcare to accelerate growth in the emerging ceramic dental implant markets - Gilde Healthcare

Swiss Dental Solutions AG partners with Gilde Healthcare to accelerate growth in the emerging ceramic dental implant ...

18. Dezember 2023
Kreuzlingen, Switzerland

Swiss Dental Solutions AG (“SDS”) today announced that Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare”), a specialized healthcare investor, has come to an agreement to acquire a majority of the shareholding of SDS through UNAC Holding AG as part of an international operational growth and development plan. Dr. Karl Ulrich Volz remains highly committed to SDS and is retaining a significant minority stake. SDS developed to become the world market leader in ceramic dental implants. This new partnership is reinforcing the leadership position and growth prospects of SDS globally.

Founded by the ceramics pioneer Dr. Karl Ulrich Volz, SDS has organically grown to become the innovative global market leader in ceramic dental implants, offering a holistic, biological, and scientifically based dental treatment concept ranging from the manufacturing of implants, provision of surgical tools and equipment, nutrition supplements, and includes an in-house clinic and education center.

The partnership with Gilde Healthcare heralds the next phase for SDS, providing access to a deep pool of knowledge in optimizing its operational development while implementing its international growth plans alongside seasoned industry experts. The commitment from Gilde Healthcare underscores the quality of SDS products and the trust in the management team to pursue and accelerate the growth trajectory and deliver on its mission to provide a clean, metal-free aesthetic dental implant solution.

Dr. Ulrich Volz, Chairman of SDS, commented: “We are thrilled to form this partnership with Gilde Healthcare, one of the premier growth partners in the industry. All the odds have changed to the favor of our ceramic implants: if it’s the guidelines, the academic interest and the scientific database, the change back to tissue level to avoid peri-implantitis and to immediate implants and immediate loading. With Gilde Healthcare’s global network, financial and human resources, SDS will be able to defend its position as innovation and market leader in the area of ceramic implants and biological dentistry, accelerate growth in the US and Europe and further improve the quality of our support to customers. Furthermore, we will benefit from their experience to further scale our organization, onboard even more talents and industry specialists in our amazing team to multiply what we have accomplished over the past 23 years in Ceramic Implantology”.

“We are very excited to partner with Dr. Ulrich Volz, and look forward to supporting the SDS team on the future growth path. SDS has built a market-leading position with their highly innovative and unique approach to biological dentistry, offering a strong foundation to accelerate organic growth. We share the team’s vision of providing a high-quality, sustainable and healthier treatment concept for surgically oriented, biological dentistry with ceramic implants”, said Robert Stein, Partner of Gilde Healthcare.

Julius Baer M&A Advisory acted as the exclusive sell-side advisor to SDS and its shareholder and assisted in structuring, marketing and negotiating the transaction.

About SDS Swiss Dental Solutions

SDS Swiss Dental Solutions is a highly innovative and quickly growing company with an extremely motivated team dedicated to the field of ceramic dental implants. Founded by the ceramics pioneer Dr. Karl Ulrich Volz, SDS is an expert in the production of ceramic implants, the provision of implant solutions made from the high-performance material zirconia to patients at the Swiss Biohealth Clinic, and the training of dentists and dental technicians in the areas of ceramic implants and biological dentistry. Thanks to the many years of experience as a producer of ceramic implants and the company’s outstanding treatment success with a focus placed on aesthetics, health and longevity at the Swiss Biohealth Clinic, SDS is the leading innovator when it comes to immunologically neutral implant restorations. SDS offers a wide range of zirconia implants with designs that have been specially adapted in line with the Swiss Biohealth Concept. The metal-free dental implant is the aesthetic solution for health that begins in the mouth.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €2.6 billion across two fund strategies: Venture&Growth and Private Equity. The Venture&Growth fund of Gilde Healthcare invests in fast growing companies active in digital health, medtech and therapeutics, based in Europe and North America. The Private Equity fund of Gilde Healthcare participates in profitable lower mid-market healthcare companies based in North-Western Europe. For more information, visit the company’s website at

For enquiries, please contact:

SDS Swiss Dental Solutions
Dr. Ulrich Volz,

Gilde Healthcare
Robert Stein,

Julius Baer M&A Advisory
Marcel Waller,

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
21. Mai 2024

Gilde Healthcare co-leads $100M equity financing in Karius

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
2. Mai 2024

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
11. April 2024